Copyright
©The Author(s) 2023.
World J Exp Med. Sep 20, 2023; 13(4): 59-74
Published online Sep 20, 2023. doi: 10.5493/wjem.v13.i4.59
Published online Sep 20, 2023. doi: 10.5493/wjem.v13.i4.59
Figure 2 Treatment options for patients with Ohtahara syndrome.
In patients with Ohtahara Syndrome with KCNQ2, SCN2A, or SCN8A mutations, there are several treatment options available. Carbamazepine, lacosamide, and phenytoin are sodium channel anti-seizure medications. These medications don’t offer a cure and are currently only used to manage the frequency of seizures. Additionally, implementation of a ketogenic diet has been shown to reduce seizure frequency in infants
- Citation: Kioutchoukova IP, Foster DT, Thakkar RN, Foreman MA, Burgess BJ, Toms RM, Molina Valero EE, Lucke-Wold B. Neurologic orphan diseases: Emerging innovations and role for genetic treatments. World J Exp Med 2023; 13(4): 59-74
- URL: https://www.wjgnet.com/2220-315X/full/v13/i4/59.htm
- DOI: https://dx.doi.org/10.5493/wjem.v13.i4.59